Cell Biology of Tumor Metastasis Formation

1989 ◽  
pp. 62-66
Author(s):  
V. Schirrmacher
2017 ◽  
Vol 44 (02) ◽  
pp. 159-166 ◽  
Author(s):  
Roger Preston ◽  
Tracy Robson ◽  
James O'Donnell ◽  
Jamie O'Sullivan

Abstractvon Willebrand factor (VWF) is a complex multimeric plasma glycoprotein that plays critical roles in normal hemostasis. However, additional novel roles for VWF in modulating cancer cell biology, and in particular tumor metastasis, have recently been reported. Markedly elevated plasma VWF levels were associated with advanced tumor stage and metastatic disease. These observations have raised the question of whether VWF may be involved in regulating tumor progression. Interestingly, novel findings indicate that VWF is expressed by a variety of tumor cells of nonendothelial origin. Critically, tumor cells that exhibit de novo acquired VWF expression demonstrate enhanced binding to endothelial cells (EC) and platelets, and increased extravasation through EC barriers. Furthermore, in vitro studies have shown that VWF can bind a variety of different tumor cells mediated by specific receptors expressed on the tumor cell surface. The concept that VWF is important in modulating tumor metastasis is further supported by in vivo experiments demonstrating that antibody-mediated VWF inhibition significantly attenuated murine metastasis. Intriguingly, however, VWF binding to specific human tumor cell lines results in apoptosis. In this study, the authors provide an overview of recent advances supporting a role for VWF in regulating multiple aspects of cancer cell biology.


2019 ◽  
Vol 26 (32) ◽  
pp. 5876-5899 ◽  
Author(s):  
Ka Ming Wong ◽  
Jiaxing Song ◽  
Vasu Saini ◽  
Yung H. Wong

It is well-recognized that the majority of cancer-related deaths is attributed to metastasis, which can arise from virtually any type of tumor. Metastasis is a complex multistep process wherein cancer cells must break away from the primary tumor, intravasate into the circulatory or lymphatic systems, extravasate, proliferate and eventually colonize secondary sites. Since these molecular processes involve the coordinated actions of numerous proteins, targeted disruptions of key players along these pathways represent possible therapeutic interventions to impede metastasis formation and reduce cancer mortality. A diverse group of proteins with demonstrated ability to inhibit metastatic colonization have been identified and they are collectively known as metastasis suppressors. Given that the metastasis suppressors are often downregulated in tumors, drug-induced re-expression or upregulation of these proteins represents a promising approach to limit metastasis. Indeed, over 40 compounds are known to exhibit efficacy in upregulating the expression of metastasis suppressors via transcriptional or post-transcriptional mechanisms, and the most promising ones are being evaluated for their translational potentials. These small molecules range from natural products to drugs in clinical use and they apparently target different molecular pathways, reflecting the diverse nature of the metastasis suppressors. In this review, we provide an overview of the different classes of compounds known to possess the ability to upregulate one or more metastasis suppressors, with an emphasis on their mechanisms of action and therapeutic potentials.


2020 ◽  
Author(s):  
Jordi Ribera ◽  
Irene Portolés ◽  
Bernat Córdoba ◽  
Juan Rodríguez-Vita ◽  
Gregori Casals ◽  
...  

ABSTRACTDHX15 is an ATP-dependent RNA helicase involved in pre-mRNA splicing and a downstream substrate for Akt1, which plays a significant role in vascular biology. The aim of this study was to explore the regulatory function of DHX15 over the vasculature and endothelial cell biology. Results: DHX15-/- was lethal in mouse and zebrafish embryos. DHX15-/- zebrafish also showed an undeveloped parachordal line, which leads to the formation of lymphatic structures. DHX15+/- mice triggered lower vascular network density and impaired lymphatic function postnatally. Transcriptome and proteome analysis of DHX15 silenced LEC revealed alterations in the glycolysis and gluconeogenesis pathways. The validation of these results demonstrated an uncoupling of the glycolysis with the oxidation of pyruvate in the mitochondria and a lower activity of the Complex I, resulting in lower cellular ATP production. Noteworthy, DHX15+/- mice partially inhibited primary tumor growth and reduced lung metastasis after injection of LLC1 tumor cells.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 342-342
Author(s):  
Liang Zhao ◽  
Aae Suzuki ◽  
Timothy J. Stalker ◽  
Lurong Lian ◽  
Min Sang ◽  
...  

Abstract It has been observed that cancer patients who have thrombocytosis frequently have metastases and a poor prognosis. Tumor metastasis formation is a complex process that involves tumor cells undergoing an intricate series of interactions with target tissues, vascular endothelium, lymphocytes, and even platelets. To test the hypothesis that platelet signaling contributes to the dissemination of tumors, we analyzed whether the disruption of phosphatidylinositol metabolism impaired metastasis formation. Phosphatidylinositol and its phosphorylated derivatives, phosphoinositides(PtdIns), are minor constituents of phospholipids at the cellular membrane level, yet they are essential components of intracellular signaling that regulate diverse cellular processes, including platelet plug formation. PtdIns are removed from cell membranes and transported through the cytoplasm by two distinct phosphatidylinositol transfer proteins (PITPs) called PITPα and PITPβ. In murine platelets, PITPα is the dominant isoform and it is present 7-fold more abundantly than PITPβ. We generated mice with a conditional deletion of PITPα specifically in platelets and in megakaryocytes, and we investigated the impact of this deletion on platelet-mediated hemostasis and tumor metastasis formation. Deletion of PITPα caused only a 15% reduction in the platelet count. However, the loss of PITPα impaired the synthesis of PtdIns(4)P and impacted the PtdIns(4,5)P2 level by 40-50% in either resting or thrombin stimulated platelets. Furthermore, deletion of PITPα resulted in an 80% reduction in platelet InsP3 production. These biochemical defects also correlated with ex vivo platelet function defects. Platelets lacking PITPα had an approximately 70~80% reduction in ex vivo platelet secretion following stimulation by low or high concentrations of thrombin, collagen, and U46619, (Thromboxane A2 analog) and ~40% reduction in platelet aggregation by low concentrations of thrombin. However, platelet accumulation area and secretion (as measured by P-selectin expression) at sites of laser-induced injuries in vivo were completely normal in mice lacking PITPα in their platelets. Therefore, despite the importance of PITPα in platelet function ex vivo, we could not demonstrate that this protein contributed to in vivo hemostasis. To determine whether PITPα-mediated phosphoinositide metabolism was critical for tumor dissemination in vivo, we utilized a well-described mouse model of lung metastasis formation following the intravenous injection of B16F10 melanoma tumor cells. We observed that lung metastasis formation was reduced by 47%±18% in mice lacking PITPα in their platelets. We also found that during the initial hours after tumor injection, control mice developed a rapid and transient thrombocytopenia. Histologic analysis revealed that tumor cell injection induced activation of wild-type platelets causing adhesion of the platelets to the melanoma cells within the vasculature. In contrast, mice with PITPα-null platelets did not become thrombocytopenic after injection with tumor cells, and also failed to form large heterogeneous complexes of platelets and melanoma cells. We also observed that in wild type mice, the tumors extravasated through the vascular wall as soon as 48 hours after injection of the melanoma cells, while this was rarely observed in mice lacking platelet PITPα. However, bronchus-associated lymphoid tissue (BALT) was strikingly hyperplastic in mice lacking platelet PITPα, but it was essentially absent in the control mice. Together, these findings demonstrate that PITPα within platelets is essential for normal phosphoinositide signaling, yet it is completely dispensable for in vivo hemostasis. In contrast, PITPα is essential for the dissemination of tumors in vivo through a complex process that involves platelet-tumor interaction and an inflammatory response that is mediated by lymphoid cells. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 418-418
Author(s):  
Liang Zhao ◽  
Lurong Lian ◽  
Aae Suzuki ◽  
Timothy J. Stalker ◽  
Sang H Min ◽  
...  

Abstract Phosphatidylinositol (PtdIns) is a relatively rare phospholipid in cell membranes. However, because of its unique ability to be transiently phosphorylated, it is critical for platelet signaling and vascular plug formation. Phosphatidylinositol transfer proteins (PITPs) facilitate the transfer of aqueous insoluble phosphatidylinositol in vitro from one cell membrane to another. Although murine platelets contain multiple PITP variants, PITPα is by far the most abundant isoform. Platelets are best known for their contribution to hemostasis, however, several lines of evidence indicate that they also contribute to tumor metastasis formation. To test the hypothesis that platelet phosphoinositide signaling contributes to tumor dissemination, we asked whether deletion of platelet PITPα impacts tumor metastasis formation by engineering PITPαfl/fl PF4Cre+ mice that lack PITPα only within their platelets and megakaryocytes. We found that loss of PITPα in platelets decreased PtdIns(4)P and PtdIns(4,5)P2 production by 30-40%. Even more striking was the 80% reduction in IP3 formation following thrombin-stimulation. However, we found no significant defect in the platelet ex vivo aggregation in response to typical doses of most of the platelet agonists, and only a small defect in response to low doses of thrombin. We investigated whether platelets lacking PITPα normally formed thrombi in vivo by using three well-established murine models. First, we observed an extremely minor (but statistically real) prolongation of the tail bleeding time in the PITPαfl/fl PF4Cre+ mice. Second, we found that mice lacking PITPα in their platelets had no defect in forming intravascular clots in response to a chemical induced carotid injury. Finally, we observed that thrombosis and platelet a-granule secretion in response to a laser-induced injury were completely normal in the knockout mice. Therefore, despite the biochemical defect in phosphoinositide signaling induced by the loss of PITPα, there was essentially no hemostastic defect. To determine whether PITPα-mediated phosphoinositide metabolism in platelets is required for tumor dissemination, we utilized a well-characterized B16F10 melanoma model of tumor metastasis. We observed that lung metastasis formation was reduced by 47%±18% in mice lacking PITPα in their platelets. We also found that during the first 3 hours after tumor injection, the control mice, but not the PITPαfl/fl PF4Cre+ mice, developed a rapid and transient thrombocytopenia. Histology analysis of the lung tissue at this time point revealed the presence of 30% more clots in the lung tissue of control mice. Further analysis showed that these thrombi were actually heterogenous complexes composed of tumor cells surrounded by platelets and fibrin. To understand why platelet PITPα influences tumor-induced fibrin formation, we investigated the ability of tumor cells to cause thrombin generation in platelet rich plasma derived from PITPαfl/fl PF4Cre+ and PITPαfl/fl PF4Cre- mice. We observed that the loss of PITPα in platelets resulted in an 88% reduction of thrombin generation compared to the controls. Furthermore, we found that PITPαfl/fl PF4Cre+ platelets also have impaired Annexin V binding suggesting that the defective fibrin formation seen in PITPαfl/fl PF4Cre+ mice is likely due to a role of PITPα in the exposure of phosphatidylserine on the platelet surface that is required for thrombin generation. Finally, we observed a mucosal immune response composed of NK-cells, T-cells, and neutrophils that was strikingly hyperplastic in mice lacking platelet PITPα at 48 hours after tumor injection, but was essentially absent in the control mice. Together, these findings demonstrate that PITPα-mediated phosphoinositide metabolism within platelets is not essential for platelet plug formation in vivo, but is required for the dissemination of tumors in vivo. Our work further demonstrates that platelet PITPα is required for tumor-induced phosphatidylserine exposure and thrombin generation. This process induces a shroud of platelets and fibrin that surround the surface of tumor cells, and thereby protects the tumors from elimination by the mucosal immune system. These results demonstrate that it is possible to clearly distinguish the platelet signaling processes required for platelet plug formation from those processes that augment metastasis formation. Disclosures No relevant conflicts of interest to declare.


Biomeditsina ◽  
2021 ◽  
Vol 17 (4) ◽  
pp. 44-49
Author(s):  
N. Yu. Timofeeva ◽  
N. V. Bubnova ◽  
G. Yu. Struchko ◽  
O. Yu. Kostrova ◽  
I. S. Stomenskaya

One of the main problems of modern medicine is cancer, which is the second leading cause of death after cardiovascular disease. Malignant neoplasms have been known for a long time; however, their study still presents significant difficulties. Modeling of malignant processes in animals allow researchers to study tumors and the main patterns of malignant growth characteristic of animals and humans. The main cause of death in malignant neoplasms is the process of metastasis formation, which remains to be understood in detail. The study of metastatic processes is one of the most important tasks of oncology. To this end, various models of tumor metastasis are created. The article reviews literature data on the most popular models of metastasis in experimental conditions. The advantages and disadvantages of the main approaches to modeling metastasis are evaluated.


2004 ◽  
Vol 3 (10) ◽  
pp. 945-951 ◽  
Author(s):  
Ke Guo ◽  
Jie Li ◽  
Jing Ping Tang ◽  
Vicki Koh ◽  
Bin Qi Gan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document